SMT201500029B - Nuovi composti di legame e modulazione dell'attivita'di fxr (NR1H4) - Google Patents
Nuovi composti di legame e modulazione dell'attivita'di fxr (NR1H4)Info
- Publication number
- SMT201500029B SMT201500029B SM201500029T SM201500029T SMT201500029B SM T201500029 B SMT201500029 B SM T201500029B SM 201500029 T SM201500029 T SM 201500029T SM 201500029 T SM201500029 T SM 201500029T SM T201500029 B SMT201500029 B SM T201500029B
- Authority
- SM
- San Marino
- Prior art keywords
- nr1h4
- modulation
- binding compounds
- new binding
- fxr activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23511709P | 2009-08-19 | 2009-08-19 | |
EP09010676A EP2289883A1 (de) | 2009-08-19 | 2009-08-19 | Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4) |
PCT/EP2010/005093 WO2011020615A1 (en) | 2009-08-19 | 2010-08-19 | Novel fxr (nr1h4 ) binding and activity modulating compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201500029B true SMT201500029B (it) | 2015-03-05 |
Family
ID=41137753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201500029T SMT201500029B (it) | 2009-08-19 | 2015-02-08 | Nuovi composti di legame e modulazione dell'attivita'di fxr (NR1H4) |
Country Status (31)
Country | Link |
---|---|
US (1) | US8952042B2 (de) |
EP (2) | EP2289883A1 (de) |
JP (1) | JP5692934B2 (de) |
KR (1) | KR101712466B1 (de) |
CN (1) | CN102548974B (de) |
AU (1) | AU2010285175B2 (de) |
BR (1) | BR112012003554A2 (de) |
CA (1) | CA2771445C (de) |
CL (1) | CL2012000369A1 (de) |
DK (1) | DK2467366T3 (de) |
EA (1) | EA024083B1 (de) |
ES (1) | ES2529226T3 (de) |
GE (1) | GEP20146109B (de) |
HK (1) | HK1172325A1 (de) |
HR (1) | HRP20150159T1 (de) |
IL (1) | IL217676A (de) |
IN (1) | IN2012DN00790A (de) |
MA (1) | MA33575B1 (de) |
ME (1) | ME02047B (de) |
MX (1) | MX2012002119A (de) |
MY (1) | MY163109A (de) |
NZ (1) | NZ598328A (de) |
PL (1) | PL2467366T3 (de) |
PT (1) | PT2467366E (de) |
RS (1) | RS53812B1 (de) |
SG (1) | SG178336A1 (de) |
SI (1) | SI2467366T1 (de) |
SM (1) | SMT201500029B (de) |
UA (1) | UA108209C2 (de) |
WO (1) | WO2011020615A1 (de) |
ZA (1) | ZA201200730B (de) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
EP2545964A1 (de) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
IL253437A0 (en) * | 2011-07-13 | 2017-09-28 | Gilead Sciences Inc | New compounds modulate fxr (nr1h4) activity and bind |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
CA2876780A1 (en) | 2012-06-26 | 2014-01-03 | Saniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
CN104411699B (zh) | 2012-06-26 | 2017-06-13 | 萨尼奥纳有限责任公司 | 苯基三唑衍生物及其用于调节gabaa 受体复合体的用途 |
WO2014001280A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
CN102976946A (zh) * | 2012-12-13 | 2013-03-20 | 烟台泰和新材料股份有限公司 | 合成间苯二甲酸二甲酯的方法 |
CN103232378B (zh) * | 2013-04-27 | 2015-11-18 | 国家海洋局第三海洋研究所 | 一种含6-溴吲哚满二酮的荔枝螺提取物及制备方法与其抗癌应用 |
WO2015036442A1 (en) | 2013-09-11 | 2015-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection |
BR112017005693A2 (pt) | 2014-09-24 | 2017-12-12 | Gilead Sciences Inc | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. |
EP3006939A1 (de) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
EP3034501A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen |
EP3034499A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Neuartige FXR (NR1H4) modulierende Verbindungen |
EP3253382B1 (de) | 2015-02-06 | 2021-11-17 | Intercept Pharmaceuticals, Inc. | Pharmazeutische zusammensetzungen für eine kombinationstherapie |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
PL3277286T3 (pl) | 2015-03-31 | 2021-11-08 | Enanta Pharmaceuticals, Inc. | Pochodne kwasu żółciowego jako agonisty fxr/tgr5 i sposoby ich stosowania |
MA41083A1 (fr) | 2015-04-07 | 2018-05-31 | Intercept Pharmaceuticals Inc | Compositions pharmaceutiques pour thérapie combinée |
WO2017128896A1 (zh) * | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
CN106995416A (zh) * | 2016-01-26 | 2017-08-01 | 上海翰森生物医药科技有限公司 | Fxr激动剂及其制备方法和应用 |
CN107021957A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
CN109152840A (zh) | 2016-03-28 | 2019-01-04 | 英特塞普特医药品公司 | 通过结合fxr激动剂和arb获得的药物 |
WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017201152A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
AR108711A1 (es) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
EP3730487B1 (de) * | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidin abkömmlinge als fxr(nr1h4)-modulierende verbindungen |
TW201808283A (zh) * | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
CN106237332A (zh) * | 2016-08-11 | 2016-12-21 | 河南大学 | 核受体fxr在肝癌干细胞靶向治疗中的应用 |
WO2018039384A1 (en) | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
CN109689050A (zh) * | 2016-09-14 | 2019-04-26 | 诺华股份有限公司 | Fxr激动剂的新方案 |
KR20180036522A (ko) * | 2016-09-30 | 2018-04-09 | (주)나노믹스 | 스틸벤 유도체 및 그 제조 방법 |
AU2017338853A1 (en) | 2016-10-04 | 2019-04-18 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
CN106588804B (zh) * | 2016-12-09 | 2018-11-09 | 都创(上海)医药科技有限公司 | 一种作为类法尼醇x受体(fxr)的化合物的制备方法 |
WO2018133730A1 (zh) * | 2017-01-20 | 2018-07-26 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
ES2959842T3 (es) | 2017-02-21 | 2024-02-28 | Genfit | Combinación de un agonista de PPAR con un agonista de FXR |
WO2018183193A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
JP2020515564A (ja) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物 |
JP7136802B2 (ja) | 2017-04-07 | 2022-09-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | スルホニルカルバマート胆汁酸誘導体の調製のためのプロセス |
WO2018190643A1 (en) * | 2017-04-12 | 2018-10-18 | Il Dong Pharmaceutical Co., Ltd. | An isoxazole derivatives as nuclear receptor agonists and used thereof |
NZ758117A (en) * | 2017-04-12 | 2022-01-28 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
CA3064794A1 (en) | 2017-05-26 | 2018-11-29 | Medshine Discovery Inc. | Lactam compound as fxr receptor agonist |
BR112020000180A2 (pt) | 2017-07-06 | 2020-07-14 | Xuanzhu (Hainan) Biopharmaceutical Co., Ltd. | agonista do receptor fxr |
CN111655680B (zh) * | 2017-09-14 | 2024-03-05 | 阿德利克斯股份有限公司 | 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂 |
JP7264906B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレーターとしてのアルケン化合物 |
AU2018360575A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
EP3704107B1 (de) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Multizyklische verbindungen als farnesoid-x-rezeptormodulatoren |
US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US11267780B2 (en) | 2018-04-30 | 2022-03-08 | The Trustees Of Indiana University | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease |
BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
ES2907187T3 (es) | 2018-08-08 | 2022-04-22 | Inorbit Therapeutics Ab | Compuestos útiles en la modulación del receptor de farnesoide X y métodos de fabricación y uso de los mismos |
DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
EP3919489A4 (de) | 2019-01-31 | 2022-10-12 | The National Institutes of Pharmaceutical R&D Co., Ltd | Aromatische ring- oder heteroaromatische ringverbindungen, verfahren zu ihrer herstellung und ihre medizinische verwendung |
US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
CN114144185A (zh) | 2019-05-30 | 2022-03-04 | 英特塞普特医药品公司 | 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物 |
JP2022540699A (ja) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
CN114945361A (zh) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN113754541A (zh) * | 2020-06-02 | 2021-12-07 | 深圳湾实验室 | 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用 |
CN117202905A (zh) | 2021-01-14 | 2023-12-08 | 埃尼奥制药公司 | Fxr激动剂和ifn用于治疗hbv感染的协同效果 |
TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
WO2023090859A1 (ko) * | 2021-11-17 | 2023-05-25 | 일동제약(주) | 아이속사졸 유도체의 제조 방법 및 그의 신규한 중간체 |
WO2023090858A1 (ko) * | 2021-11-17 | 2023-05-25 | 일동제약(주) | 아이속사졸 유도체의 제조 방법 및 그의 중간체 |
WO2024005586A1 (ko) * | 2022-06-30 | 2024-01-04 | 일동제약(주) | 아이속사졸 유도체 또는 이의 염의 신규한 결정형 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6639078B1 (en) | 1998-12-23 | 2003-10-28 | Smithkline Beecham Corporation | Assays for ligands for nuclear receptors |
EP1285914B1 (de) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4-kern-rezeptor-bindende verbindungen |
AU2003225903A1 (en) | 2002-03-21 | 2003-10-08 | Curagen Corporation | Methods of using farnesoid x receptor (fxr) agonists |
EP1562915A1 (de) * | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x rezeptor agonisten |
WO2004087076A2 (en) | 2003-03-31 | 2004-10-14 | The Rockefeller University | Methods for inhibiting adipogenesis and for treating type 2 diabetes |
JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドx受容体アゴニスト |
CA2640476A1 (en) | 2006-02-03 | 2007-08-16 | Eli Lilly And Company | Compounds and methods for modulating fx-receptors |
US8106077B2 (en) | 2006-05-24 | 2012-01-31 | Eli Lilly And Company | Compounds and methods for modulating FXR |
US7846960B2 (en) | 2006-05-24 | 2010-12-07 | Eli Lilly And Company | FXR agonists |
EP1894928A1 (de) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Fxr bindende heterocyclische verbindungen |
EP1894924A1 (de) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterozyklische FXR Bindungsverbindungen |
CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
WO2008157270A1 (en) | 2007-06-13 | 2008-12-24 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
CN101877966A (zh) | 2007-07-02 | 2010-11-03 | 葛兰素史密丝克莱恩有限责任公司 | 类法尼醇x受体激动剂 |
TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
-
2009
- 2009-08-19 EP EP09010676A patent/EP2289883A1/de not_active Withdrawn
-
2010
- 2010-08-19 SG SG2012009072A patent/SG178336A1/en unknown
- 2010-08-19 IN IN790DEN2012 patent/IN2012DN00790A/en unknown
- 2010-08-19 MY MYPI2012000379A patent/MY163109A/en unknown
- 2010-08-19 WO PCT/EP2010/005093 patent/WO2011020615A1/en active Application Filing
- 2010-08-19 SI SI201030858T patent/SI2467366T1/sl unknown
- 2010-08-19 DK DK10747171.6T patent/DK2467366T3/en active
- 2010-08-19 CN CN201080037300.7A patent/CN102548974B/zh active Active
- 2010-08-19 PL PL10747171T patent/PL2467366T3/pl unknown
- 2010-08-19 CA CA2771445A patent/CA2771445C/en active Active
- 2010-08-19 US US13/390,499 patent/US8952042B2/en active Active
- 2010-08-19 PT PT107471716T patent/PT2467366E/pt unknown
- 2010-08-19 MX MX2012002119A patent/MX2012002119A/es active IP Right Grant
- 2010-08-19 JP JP2012525089A patent/JP5692934B2/ja active Active
- 2010-08-19 KR KR1020127006908A patent/KR101712466B1/ko active IP Right Grant
- 2010-08-19 EA EA201290047A patent/EA024083B1/ru unknown
- 2010-08-19 UA UAA201203007A patent/UA108209C2/ru unknown
- 2010-08-19 ME MEP-2015-18A patent/ME02047B/me unknown
- 2010-08-19 BR BR112012003554A patent/BR112012003554A2/pt not_active Application Discontinuation
- 2010-08-19 NZ NZ598328A patent/NZ598328A/xx unknown
- 2010-08-19 RS RS20150079A patent/RS53812B1/en unknown
- 2010-08-19 GE GEAP201012606A patent/GEP20146109B/en unknown
- 2010-08-19 ES ES10747171.6T patent/ES2529226T3/es active Active
- 2010-08-19 AU AU2010285175A patent/AU2010285175B2/en active Active
- 2010-08-19 EP EP10747171.6A patent/EP2467366B1/de active Active
-
2012
- 2012-01-22 IL IL217676A patent/IL217676A/en active IP Right Grant
- 2012-01-30 ZA ZA2012/00730A patent/ZA201200730B/en unknown
- 2012-02-13 CL CL2012000369A patent/CL2012000369A1/es unknown
- 2012-03-08 MA MA34676A patent/MA33575B1/fr unknown
- 2012-12-18 HK HK12113083.7A patent/HK1172325A1/xx unknown
-
2015
- 2015-02-08 SM SM201500029T patent/SMT201500029B/xx unknown
- 2015-02-09 HR HRP20150159TT patent/HRP20150159T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201500029B (it) | Nuovi composti di legame e modulazione dell'attivita'di fxr (NR1H4) | |
CY2019010I1 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
ZA201309521B (en) | Novel fxr (nr1h4)binding and activity modulating compounds | |
DK3225251T3 (da) | Modulering af pro-neurotrofinaktivitet | |
ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
SMT201500047B (it) | Agenti leganti il recettore notch1 e loro metodi d'uso | |
DK2117523T3 (da) | Inhibitorer af AKT-aktivitet | |
BRPI0918586A2 (pt) | compostos, composições e métodos de uso dos mesmos para a modulação dos níveis de ácido úrico | |
ATE537147T1 (de) | Azabiphenylaminobenzoesäurederivate als dhodh- inhibitoren | |
ATE519835T1 (de) | Verwendung von zitrat als reinigungshilfe für harte oberflächen | |
ZA201104235B (en) | Companion animal compositions including lipoic acid and methods of use thereof | |
ATE543816T1 (de) | Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase | |
FI20065757A (fi) | Beta-laktamaasin käyttö | |
IT1397247B1 (it) | Nuovi agenti regolatori dell'attivita' citochinica | |
BRPI0917210A2 (pt) | exoterma controlada de formulações de cianocrilato | |
DK2240154T3 (da) | Kosmetisk sammensætning omfattende glycogentil anvendelse med fløjlsblød virkning | |
BRPI0915927A2 (pt) | uso de inibiodores de hdac para o tratamento da doença de hodgkin | |
DK2173197T3 (da) | Fremgangsmåde | |
FI20085102A (fi) | Probioottien uusi käyttö | |
DE602006006853D1 (de) | Synthese von neuem Dihydrobenzoxazin | |
UY33134A (es) | Profarmacos de [4 [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il] -(1h-pirrolo-piridin-il)-metanonas y sintesis de estos. | |
IL277570A (en) | New compounds that modulate FXR activity and bind (NR1H4)FXR | |
TH0801006114A (th) | สารประกอบและองค์ประกอบใหม่ และวิธีการของการใช้ | |
FR2938285B1 (fr) | Panneton d'espagnolette | |
TH0901000920A (th) | สารประกอบ และองค์ประกอบในฐานะตัวปรับแอคติวิตี้ของ tlr |